gms | German Medical Science

Deutscher Rheumatologiekongress 2023

51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh)
37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh)
33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR)

30.08. - 02.09.2023, Leipzig

Artikel

Artikel empfehlen

Sex differences in cytokine levels and PBMC subsets in axial Spondyloarthritis

Meeting Abstract

Suche in Medline nach

  • Mia Juditzki - Leibniz-Institut für Arbeitsforschung an der TU Dortmund, Immunology, Research Group of Neuroimmunology, Dortmund
  • Dimitra Karagkiozidou - Rheumazentrum Ruhrgebiet, Herne
  • Styliani Tsiami - Rheumazentrum Ruhrgebiet, Herne
  • Christian Schütz - Rheumazentrum Ruhrgebiet, Herne
  • Xenofon Baraliakos - Rheumazentrum Ruhrgebiet, Herne
  • Silvia Capellino - Leibniz-Institut für Arbeitsforschung an der TU Dortmund, Immunology, Research Group of Neuroimmunology, Dortmund

Deutsche Gesellschaft für Rheumatologie. Deutsche Gesellschaft für Orthopädische Rheumatologie. Gesellschaft für Kinder- und Jugendrheumatologie. Deutscher Rheumatologiekongress 2023, 51. Kongress der Deutschen Gesellschaft für Rheumatologie (DGRh), 37. Jahrestagung der Deutschen Gesellschaft für Orthopädische Rheumatologie (DGORh), 33. Jahrestagung der Gesellschaft für Kinder- und Jugendrheumatologie (GKJR). Leipzig, 30.08.-02.09.2023. Düsseldorf: German Medical Science GMS Publishing House; 2023. DocSpA.27

doi: 10.3205/23dgrh198, urn:nbn:de:0183-23dgrh1985

Veröffentlicht: 30. August 2023

© 2023 Juditzki et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.

Gliederung

Text

Introduction: Disease progression, treatment efficacy and several inflammatory biomarkers are differentially pronounced in females and males suffering from axial Spondyloarthritis (axSpA), suggesting that there are sex-specific differences in the pathophysiology of axSpA. Nevertheless, knowledge of sex-specific differences in axSpA pathology is still limited and treatment response is worse in female patients. The aim of this study is therefore to delineate sex-specific differences in axSpA-related biomarkers and peripheral blood mononuclear cell (PBMC) subsets in biologically naïve nr-axSpA and r-axSpA patients.

Methods: Plasma samples from biologically naïve nr-axSpA (males n=9, females n=6) and r-axSpA (males n=26, females n=10), with high disease activity, and age-matched back pain controls (males n=7, females n=14) were analyzed for levels of HGF, IL-6, IL-10, IL-12(p40), TNF-a, VEGF, IL-17A, IL-22, IL-23, MMP-3, Osteocalcin and Osteopontin by multiplex analysis. PBMC subsets were differentiated by flow cytometry utilizing specific extracellular markers.

Results: In consistency with other studies, we found higher levels of IL-6 in r-axSpA females than in males but notably male nr-axSpA patients exhibit significantly higher plasma IL-6 levels than females (p<0,05). In addition, male r-axSpA patients had a higher MMP-3 concentration than females (p<0,05). Interestingly, HGF levels were significantly higher in nr-axSpA males than in nr-axSpA females (p<0,05). So far, flow cytometry data did not reveal any significant differences in frequencies of PBMC subsets between males and females suffering from either nr- or r-axSpA.

Conclusion: Our data demonstrate that the plasma expression of pathogenetically relevant biomarkers such as IL-6, HGF and MMP-3 is sex- and moreover disease subgroup- (nr-/r-axSpA) specific, supporting the necessity and clinical relevance of further sex- and disease-subgroup-specific analysis. This will help to define sex- and group-specific therapeutic targets and to develop new personalized treatment strategies, thus improving therapy response.

Disclosure: Nothing to disclose.